Nathan Jorgensen

Nathan Jorgensen is an accomplished financial executive with extensive experience in the healthcare and biotechnology sectors. Currently serving as Chief Financial Officer at Voyager Therapeutics, Inc., Nathan previously held the same position at Vor Bio, where oversight included finance, communications, facilities, GMP, and IT for a clinical-stage cell and genome engineering company. Nathan also contributed as a Board Member at OncoResponse and as Senior Manager of the Healthcare Portfolio at the Qatar Investment Authority, focusing on global healthcare investments. Prior experience includes roles as Senior Research Analyst at Calamos Investments and Associate Research Analyst at Stifel Nicolaus, along with consultancy and advisory positions in competitive intelligence and strategic development. Nathan holds an MBA from Cornell Johnson Graduate School of Management, a Ph.D. in Neuroscience from the University of Minnesota, and a BA from Saint John’s University.